Aurinia Pharmaceuticals Inc.

Listed Company

AUPHCIK 0001600620NasdaqLarge AcceleratedPharmaceutical PreparationsCAFY ends Dec 31

Period

FY 2025

Revenue

$283.06M

Net Income

$287.20M

Total Assets

$751.59M

Equity

$581.33M

Shares Out

132.97M

Op. Cash Flow

$135.66M

Business

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases, particularly lupus nephritis. The company’s primary product is LUPKYNIS (voclosporin), an oral calcineurin-inhibitor indicated for adult patients with active lupus nephritis, and it is developing AUR200, a dual BAFF/APRIL inhibitor for autoimmune conditions. Aurinia operates commercial, research and development, and manufacturing/supply chain functions, including collaborations for manufacturing and commercialization. It sells LUPKYNIS in the U.S. through specialty pharmacies and a distributor and supplies inventory to its collaboration partner, Otsuka, for markets in Europe and Japan.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenue	283	235	176	134	46
Cost of revenue	33	28	14	6	1
Selling, general and administrative	102	172	195	196	174
Research and development	33	21	50	45	51
Restructuring	2	23	0	0	—
Other expense (income), net	10	−4	8	−2	574,000
Total operating expenses	178	240	267	246	226
Income (loss) from operations	105	−5	−92	−111	−181
Interest income	14	17	17	5	—
Interest expense	−4	−5	−3	0	—
Net income (loss) before income taxes	114	7	−77	−106	−180
Income tax (benefit) expense	−173	2	551,000	2	760,000
Net income (loss)	287	6	−78	−108	−181
Unrealized gain on available-for-sale securities	48,000	83,000	331,000	−209,000	−47,000
Comprehensive income (loss)	287	6	−78	−108	−181
Basic (in usd per share)	2.14	0.04	−0.54	−0.76	−1.4
Diluted (in usd per share)	2.07	0.04	−0.54	−0.76	−1.4
Basic (in shares)	134	143	143	142	129
Diluted (in shares)	139	146	143	142	129

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash, cash equivalents and restricted cash	80	83	49	94	232
Short-term investments	318	275	302	295	234
Accounts receivable, net	41	37	24	14	15
Inventory	46	39	40	25	19
Prepaid expenses and deposits	6	11	9	—	—
Other current assets	1	1	1	1	796,000
Total current assets	492	447	425	443	513
Deferred tax assets, net	176	0	—	—	—
Finance right-of-use lease assets	74	92	109	0	—
Intangible assets, net	4	4	5	6	8
Operating right-of-use lease assets	4	4	4	5	5
Property and equipment, net	2	3	3	4	4
Other noncurrent assets	93,000	823,000	2	13	12
Total assets	752	551	548	471	543
Accounts payable	3	5	4	—	—
Accrued expenses	67	65	50	—	—
Finance lease liabilities, current portion	17	14	15	0	—
Deferred revenue	4	11	5	3	190,000
Operating lease liabilities, current portion	1	1	989,000	936,000	1
Other current liabilities	2	2	2	2	4
Total current liabilities	94	98	77	46	41
Finance lease liabilities, less current portion	52	59	75	0	—
Deferred revenue, less current portion	13	2	—	—	—
Deferred compensation and other noncurrent liabilities	7	9	—	—	—
Operating lease liabilities, less current portion	5	6	7	7	8
Total liabilities	170	173	170	65	64
Commitments and contingencies (Note 5)	—	—	—	—	—
Common shares - no par value, Unlimited shares authorized, 132,323 and 140,883 shares issued and outstanding at December 31, 2025 and 2024, respectively	1,120	1,188	1,200	1,185	1,177
Additional paid-in capital	111	127	121	85	59
Accumulated other comprehensive loss	−599,000	−647,000	−730,000	−1	−852,000
Accumulated deficit	−649	−937	−942	−864	−756
Total shareholders' equity	581	377	378	405	479
Total liabilities and shareholders' equity	752	551	548	471	543

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Deferred income tax benefit	−176	0	0	—	—
Amortization and depreciation	19	19	12	3	3
Share-based compensation	15	32	45	32	31
Foreign exchange loss (gain) on revaluation of Monoplant finance lease liability	10	−6	6	0	—
Net amortization of premiums and discounts on investments	−10	−13	−12	−2	660,000
Non-cash write-down of inventory	0	0	916,000	4	245,000
Other, net	−200,000	788,000	−2	−2	−2,000
Accounts receivable, net	−5	−12	−11	2	−15
Inventory	−6	477,000	−16	−9	−6
Prepaid expenses and other current assets	6	−2	4	−2	−5
Other noncurrent operating assets	730,000	31,000	−16,000	−363,000	353,000
Accounts payable	−2	860,000	1	−792,000	—
Accrued expenses and other liabilities	−5	13	12	1	—
Deferred revenue	4	6	4	3	0
Operating lease liabilities	−802,000	−750,000	−673,000	−652,000	332,000
Cash flows from operating activities	136	44	−33	−80	−158
Proceeds from the sale and maturities of investments	494	585	529	464	354
Purchases of investments	−527	−546	−524	−524	−439
Upfront lease payments	0	−43,000	−12	−663,000	−12
Purchases of property, equipment and intangible assets	−252,000	−281,000	−718,000	−292,000	−303,000
Cash flows from investing activities	−33	39	−7	−61	−104
Repurchase of common shares	−98	−40	0	0	—
Principal portion of finance lease payments	−13	−12	−10	0	0
Proceeds from issuance of common shares from exercise of stock options and vesting of RSUs and performance awards	14	8	5	2	24
Proceeds from issuance of common shares under ESPP	756,000	1	2	2	197
Taxes paid related to net settlement of exercises of stock options and vesting of RSUs and performance awards	−10	−6	−2	−1	—
Cash flows from financing activities	−106	−49	−5	2	221
Net (decrease) increase in cash, cash equivalents and restricted cash	−3	35	−45	−138	−40
Finance lease liability arising from obtaining right-of-use assets	0	0	94	0	—
Cash paid for income taxes	−3	−2	−496,000	−2	—
Taxes withheld related to vesting of performance awards	4	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro